Compare Hyatt Hotels Corporation (H) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Hyatt Hotels Corporation trades at $161.84 (market cap $15.02B), while State Street SPDR S&P Biotech ETF trades at $153.99 (market cap $10.11B). The key difference: Hyatt Hotels Corporation is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| H | XBI | |
|---|---|---|
Market Cap | $15.02B | $10.11B |
Volume | 842,340 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $202.09 | $169.55 |
52-Week Low | $135.42 | $104.99 |
Typical Hold Time | 148 Days | 38 Days |
Enterprise Value | $18.93B | — |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $161.75, up 2.93% with recent earnings beats driving momentum. The stock shows neutral technical signals with mixed moving averages and oscillators. Fundamentally, revenue grew to $7.1B in 2025 but net income turned negative at -$52M, while valuation metrics remain elevated with P/E at 196.83. Recent developments include strategic partnerships with Delta Air Lines and expansion of the Essentials portfolio.
Outlook remains cautiously optimistic with analyst consensus target of $197.77 (22% upside) but high valuation and negative cash flow trends pose risks. The company's growth initiatives and brand expansion provide opportunities, though investors should monitor debt levels and profitability recovery.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
